Assessing the Association of Appropriateness of Coronary Revascularization and Clinical Outcomes for Patients With Stable Coronary Artery Disease  by Ko, Dennis T. et al.
Journal of the American College of Cardiology Vol. 60, No. 19, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Coronary Artery Disease
Assessing the Association of Appropriateness of
Coronary Revascularization and Clinical Outcomes
for Patients With Stable Coronary Artery Disease
Dennis T. Ko, MD, MSC,*†‡ Helen Guo, MSC,* Harindra C. Wijeysundera, MD, PHD,*†‡
Madhu K. Natarajan, MD, MSC,§ A. Dave Nagpal, MD, Christopher M. Feindel, MD,‡¶
Kori Kingsbury, MSN,# Eric A. Cohen, MD,†‡ Jack V. Tu, MD, PHD,*†‡ for the Cardiac Care
Network (CCN) of Ontario Variations in Revascularization Practice in Ontario (VRPO) Working Group
Toronto, Hamilton, and London, Ontario, Canada
Objectives The study assessed the appropriateness of coronary revascularization in Ontario, Canada, and examined its as-
sociation with longer-term outcomes.
Background Although appropriate use criteria for coronary revascularization have been developed to improve the rational use
of cardiac invasive procedures, it is unknown whether greater adherence to appropriateness guidelines is associ-
ated with improved clinical outcomes in stable coronary artery disease.
Methods A population-based cohort of stable patients undergoing cardiac catheterization was assembled from April 1, 2006,
to March 31, 2007. The appropriateness for coronary revascularization at the time of coronary angiography was retro-
spectively adjudicated using the appropriate use criteria. Clinical outcomes between coronary revascularization and
medical treatment without revascularization, stratified by appropriateness categories, were compared.
Results In 1,625 patients with stable coronary artery disease, percutaneous coronary intervention or coronary artery by-
pass grafting was only performed in 69% who had an appropriate indication for coronary revascularization. Coro-
nary revascularization was associated with a lower adjusted hazard of death or acute coronary syndrome (hazard
ratio [HR]: 0.61; 95% confidence interval [CI]: 0.42 to 0.88) at 3 years compared with medical therapy in appro-
priate patients. The rate of coronary revascularization was 54% in the uncertain category and 45% in the inap-
propriate category. No significant difference in death or acute coronary syndrome between coronary revascular-
ization and no revascularization in the uncertain category (HR: 0.57; 95% CI: 0.28 to 1.16) and the inappropriate
category (HR: 0.99; 95% CI: 0.48 to 2.02) was observed.
Conclusions Using the appropriateness use criteria, we identified substantial underutilization and overutilization of coronary revas-
cularization in contemporary clinical practice. Underutilization of coronary revascularization is associated with signifi-
cantly increased risks of adverse outcomes in patients with appropriate indications. (J Am Coll Cardiol 2012;60:
1876–84) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.056Marked regional variations in the use of coronary revascu-
larization continue to exist in Canada and in the United
States (1–5). It is well documented that these discrepancies
are not fully explained by differences in demographics and
clinical factors but are in part related to the local practice
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November 6, 2012:1876–84 Appropriateness of Coronary Revascularizationimprove the rational use of coronary revascularizations (6,7).
he appropriate use criteria for coronary revascularization
ere recently developed by the American College of Car-
iology Foundation and 5 other professional organizations in
he United States (6). Using the Delphi panel methodology, an
xpert panel rated a large number of common clinical scenarios
nd categorized coronary revascularizations as appropriate,
ncertain, or inappropriate (6). Coronary revascularization is
onsidered appropriate when the expected benefits exceeded
he expected negative consequences of the procedure (6).
onversely, coronary revascularization is considered inappro-
riate when it is unlikely to improve the patient’s health
utcomes or survival (6). These criteria were recently applied
y Chan et al. (7), who found that only about half of all
atients undergoing percutaneous coronary intervention
PCI) procedures in the United States for nonacute indica-
ions were considered appropriate.
Despite the vigorous process that has been put forth for
heir development, many ratings in the appropriate use
riteria were based on experts’ opinion and their knowledge
f the clinical literature. Accordingly, the validity of the
ppropriateness use criteria remains unknown. Specifically,
o patients with appropriate indications who received cor-
nary revascularization have better outcomes than patients
reated with medical therapy in clinical practice? Do pa-
ients with inappropriate indications who received coronary
evascularization fare worse compared with those that did
ot? Validation of appropriate use criteria for coronary
evascularization in the real world is essential before they are
idely disseminated as a measure of quality of care and/or to
ake reimbursement decisions. Accordingly, our main ob-
ective was to perform a population-based study to evaluate
he association between appropriateness of coronary revas-
ularization and longer-term outcomes.
ethods
ystem context. The Ontario government reimburses all
ardiac invasive procedures for its citizens without user fees
r copayments (2). Provision of cardiac invasive procedures
s regionalized in Ontario. There are currently 18 cardiac
nvasive centers in Ontario serving a population of 13.2
illion people. In these centers, 11 perform PCI and
oronary artery bypass grafting (CABG) surgery, 3 are
tand-alone PCI centers without cardiac surgery backup,
nd 4 perform only cardiac catheterization. More than
5,000 cardiac catheterizations, 20,000 PCIs, and 8,000
ABGs are performed annually in the province.
he VRPO study. The VRPO (Variation in Revascular-
zation Practices in Ontario) study was conducted by the
ardiac Care Network (CCN) of Ontario in partnership
ith the Institute for Clinical Evaluative Sciences to exam-
ne variations in the use of PCI and CABG across the
rovince (8). A retrospective chart review was conducted on
atients undergoing cardiac catheterization from April 1,
006, to March 31, 2007, at all the Ontario cardiac invasive denters. A population-based sample
f 8,972 patents was randomly
elected from the CCN of On-
ario cardiac invasive procedure
atabase. This study sample rep-
esented 20% of all angiograms
erformed in the province at the
ime of the study. Experienced
ardiology research nurses ab-
tracted detailed clinical infor-
ation from hospital charts fo-
using on data variables used in
he appropriate use criteria for
oronary revascularization that
ncluded: 1) clinical presentation and symptom severity;
) intensity of anti-ischemic medical therapy; 3) ischemic
urden as determined by noninvasive testing; and 4) extent
f coronary artery stenosis on coronary angiography (6,7).
tudy sample. The study sample for this analysis was
estricted to patients undergoing cardiac catheterization at
ll the cardiac invasive facilities in Ontario for a suspected
iagnosis of coronary artery disease. We did not include
atients with acute indications for coronary angiography
uch as myocardial infarction or unstable angina because a
revious study has shown almost all coronary revasculariza-
ions to be appropriate (7). We excluded patients who had
ardiac catheterization or PCI in the year preceding the
ndex procedure in order to capture an inception cohort of
atients undergoing coronary angiography. We also ex-
luded patients with prior CABG. We included only those
atients with coronary artery disease, defined as luminal
tenosis greater than 50%, because the appropriateness use
riteria did not consider patients with normal to mild
oronary artery disease. Only patients with a valid health
ard number were included in the study.
utcomes. Coronary revascularization procedures (PCI or
ABG) occurring within 60 days after the index cardiac
atheterization were determined by the CCN database,
hich tracks clinical data on all cardiac invasive procedures
n the province (9). The primary long-term outcome mea-
ure was a composite of all-cause mortality and recurrent
ospitalizations for acute coronary syndrome (ACS). Mor-
ality was determined using the Ontario Registered Persons
atabase. Recurrent hospitalization for ACS (myocardial
nfarction or unstable angina) was identified from the
anadian Institute for Health Information Discharge Ab-
tract Database (International Classification of Diseases,
0th revision, disease codes I20, I21, I22, I23.82, I24) (10).
omplete follow-up data were available for all patients
hrough March 31, 2010.
tatistical analysis. The appropriateness for coronary re-
ascularization at the time of coronary angiography was
etrospectively adjudicated using the appropriate use crite-
ia. Each cardiac catheterization procedure was assigned an
ppropriateness score from 1 to 9, with a score of 7 to 9
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
CI  confidence interval
CCN  Cardiac Care
Network of Ontario
HR  hazard ratio
PCI  percutaneous
coronary interventionenoting the patient had an appropriate indication for
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Appropriateness of Coronary Revascularization November 6, 2012:1876–84coronary revascularization, a score of 4 to 6 denoting
uncertain indication, and a score of 1 to 3 denoting
inappropriate indication (6). Patients were then followed to
determine the treatment they received following the coro-
nary angiography. This construct not only allowed us to
determine the use of coronary revascularization among
patients with appropriate, uncertain, and inappropriate in-
dications, but also enabled us to examine patients who were
treated medically (no coronary revascularization) in different
appropriateness categories.
To assess the association between appropriateness of
coronary revascularization and longer-term outcomes, we
compared the outcomes of patients who were treated with
coronary revascularization and medical therapy, according
to their appropriateness categories in pre-specified analysis,
which was consistent with prior studies in the literature
(11,12). In other words, we compared outcomes of revas-
cularization versus no revascularization in patients with
appropriate, uncertain, and inappropriate indications in
stratified analyses. It is important to note that coronary
revascularization patients also received medical therapy, and
thus, our analyses examined the incremental benefit of
coronary revascularization on top of medical therapy. We
used appropriate statistical tests (chi-square test for categor-
ical variables and t tests for continuous variables) to compare
haracteristics of patients treated with coronary revascular-
zation and medical therapy. Multivariable proportional
azards models were used to adjust for the potential impact
f confounding factors between the treatment groups in
ach appropriateness stratum. Coronary revascularization
ithin 60 days of the coronary angiography was modeled as
ime-varying exposure to account for the potential difference
n revascularization time after the index cardiac catheteriza-
ion. The use of a time-dependent covariate enabled the
reatment variable to vary during the observation period
fter cardiac catheterization and allowed us to minimize the
mpact of survivorship bias by estimating the effect of
urrent exposure on the instantaneous hazard of adverse
utcomes compared with medical therapy. Candidate vari-
bles of interests were selected based on clinical knowledge
hat included demographics (age, sex), severity of angina,
xtent of coronary artery disease, cardiac risk factors (hyper-
ension, diabetes, hyperlipidemia), comorbidities (prior myo-
ardial infarction, prior heart failure, peripheral vascular dis-
ase, chronic obstructive pulmonary disease, and peripheral
ascular disease), physician characteristics (invasive or interven-
ional cardiologist), and hospital characteristics (ability to
erform cardiac catheterization only, cardiac catheterization
nd PCI, or cardiac catheterization, PCI, and CABG).
A series of sensitivity analyses were undertaken to exam-
ne the robustness of our results. First, we examined the
mpact of including variables used to categorize appropri-
teness categories (e.g., symptom severity, medical therapy,
oninvasive testing, and coronary stenosis) in all the adjust-
ent models. Second, we reanalyzed our results by including
robust variance estimator to account for the potential impact tf clustering of hospitals (13). In the previous sensitivity
nalyses, our overall results did not significantly change.
All 2-sided p values 0.05 were considered statistically
ignificant. SAS version 9.2 (SAS Institute, Cary, North
arolina) was used to conduct the analyses.
esults
tudy sample. The creation of the study sample is shown
n Figure 1. The VRPO study included data on 8,972
atients undergoing coronary angiography. There were
,625 patients who had stable coronary artery disease
ithout prior CABG, coronary angiogram, or PCI in the
revious year. We excluded 1,495 patients who had normal
o mild coronary arteries. In addition, we were also not able
o assign appropriateness scores to 224 patients because of
orderline coronary stenosis, 103 patients because of lack of
schemic evaluation prior to coronary revascularization, and
20 patients due to lack of documented angina classifica-
ion. Our final dataset for analysis included 1,628 patients.
ate of coronary revascularization according to
ppropriateness category. The distribution of appropri-
teness scores in our cohort is shown in Figure 2. At the
ime of the coronary angiography, 61% of patients with
ignificant coronary artery stenosis had appropriate indica-
ions for coronary revascularization, 20% had uncertain
ndications, and 19% had inappropriate indications. Among
atients who received coronary revascularization, 68% of all
rocedures were considered appropriate, 18% were consid-
red uncertain, and 14% were considered inappropriate.
Of the 991 patients who had appropriate indications,
oronary revascularization was performed in 69% (Fig. 3,
able 1). PCI was the mode of coronary revascularization in
7% of appropriate patients and 43% received CABG. Of
he 326 patients classified as uncertain candidates, 54%
nderwent coronary revascularization in which 86% received
CI as the mode of revascularization. Of the 311 patients
ho had inappropriate indications, 45% underwent coro-
ary revascularization, most (82%) via PCI procedures.
Among the 997 patients who received coronary revascu-
arization, 68% were considered appropriate, 18% were
onsidered uncertain, and 14% were considered inappropri-
te. For the 654 patients who received PCI, 60% of all PCIs
ere considered appropriate, 23% were uncertain, and 18%
ere inappropriate. For the 343 patients undergoing
ABG, the majority of patients (85%) were considered
ppropriate, 8% were uncertain, and 7% were inappropriate.
aseline characteristics according to treatment and
ppropriateness categories. The baseline characteristics of
atients treated with coronary revascularization and medical
herapy with no revascularization, stratified by appropriate-
ess categories, are shown in Table 1. Among patients with
ppropriate indications, those who received coronary revas-
ularization were slightly younger, were less likely to have
ardiac risk factors, and had no prior cardiac history. The 2
reatment groups did not differ significantly in symptom
1879JACC Vol. 60, No. 19, 2012 Ko et al.
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of coronary artery disease, which were factors used to
categorize the appropriateness scores.
Similar trends were also observed in the baseline charac-
teristics among uncertain and inappropriate indications, in
which patients who received coronary revascularization were
younger and had slightly fewer medical and cardiac condi-
tions. One of the largest differences in the uncertain
category was physician characteristics, as interventional
cardiologists performed 42% of the cardiac catheterization
in patients who subsequently received coronary revascular-
ization versus only performing 26% in the no revasculariza-
tion group (p  0.002) (Table 1).
Association of coronary revascularization and outcomes
across appropriateness categories. In patients who had
appropriate indication for coronary revascularization, the
composite unadjusted endpoint of death and recurrent ACS
at 3 years occurred in 11.8% in the coronary revasculariza-
tion group compared with 16.1% in the no revascularization
Figure 1 Creation of the Study Sample
The diagram details the way the final study sample of 1,628 patients was created
CCS  Canadian Cardiovascular Society; STEMI  ST-segment elevation myocardigroup (Table 2). At 3 years, mortality was 3.8% in thecoronary revascularization group and 9.0% in the no revas-
cularization group; repeat ACS was 9.4% in the coronary
revascularization group and 9.9% in the no revascularization
group. Coronary revascularization was associated with a
lower hazard of death or repeat ACS (hazard ratio [HR]:
0.61; 95% confidence interval [CI]: 0.42 to 0.88) after
adjusting for differences in demographics, comorbidities,
and physician and hospital characteristics (Table 2). Pa-
tients undergoing CABG had a significantly lower hazard
(HR: 0.33; 95% CI: 0.18 to 0.61) as compared with medical
therapy, whereas no significant reduction in hazard associ-
ated with PCI was observed (HR: 0.83; 95% CI: 0.54 to
1.26). The HR associated with CABG was significantly
different as compared with PCI (p  0.006).
In the uncertain category, unadjusted event rates at 3
years among the coronary revascularization group and the
no revascularization group were 8.0% and 15.3% for death
or repeat ACS, 2.3% and 12.7% for mortality, 5.6% and
5.3% for repeat ACS. Coronary revascularization was not
 coronary artery bypass grafting; CAD  coronary artery disease;
rction; VRPO  Variations in Revascularization Practices in Ontario.. CABG
al infasignificantly associated with a reduction of death or ACS
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category, unadjusted event rates at 3 years among the
coronary revascularization group and the no revasculariza-
tion group were 14.2% and 9.4% for death or repeat ACS,
2.8% and 5.3% for mortality, 12.0% and 5.3% for repeat
ACS. Similarly, no significant difference in the adjusted
hazard of death and repeat ACS (HR: 0.99; 95% CI: 0.48
to 2.02) between the treatment groups in patients who had
an inappropriate indication (Table 2).
Discussion
Our study provides validation to the appropriate use criteria
by demonstrating not receiving revascularization among
appropriate candidates was associated with significantly
increased risks of adverse events compared with those who
had undergone revascularization. In our population-based
cohort of patients with stable coronary artery disease, we
found that 68% of all coronary revascularizations were
considered appropriate, 18% were considered uncertain, and
14% were considered inappropriate. We also found under-
utilization of coronary revascularization in which more than
30% of patients with appropriate indications did not receive
revascularization. By contrast, although the absolute num-
ber of uncertain and inappropriate coronary revasculariza-
tions was low, almost 50% of patients who had uncertain or
inappropriate indications at coronary angiography received
Figure 2 Distribution of Appropriateness Score
Distribution of the appropriateness score in patients with stable coronary artery di
indication, a score of 4 to 6 indicates uncertain indication, and a score of 7 to 9
of Cardiology.coronary revascularization.In a large PCI cohort in the United States, it was recently
demonstrated that more than 98% of the procedures in
patients with acute indications were considered appropriate
(7). For patients with nonacute indications, however, it was
shown that PCI procedures were considered appropriate in
only 50%, uncertain in 38%, and inappropriate in 12% (7).
Other studies have shown that the United States perform
substantially more coronary revascularization procedures as
compared with Canada in patients with stable coronary
artery disease (2,14). Our data suggest higher revasculariza-
tion rates in the United States may in part be related to
higher rates of revascularization in patients with uncertain
indications. Future evaluation is needed to confirm whether
discrepancies in appropriateness of coronary revascularization
exist and whether they can be attributed to differences in
implicit and explicit incentives associated with the different
models of healthcare financing between the 2 countries.
Our findings extend prior knowledge and provide new
insights into the appropriateness of coronary revasculariza-
tion in current clinical practice. By assessing the appropri-
ateness of coronary revascularization at the time of coronary
angiography and following patients for treatment strategies,
we were able to demonstrate underutilization (i.e., patients
with appropriate indication but no revascularization) and
overutilization (i.e., patients with inappropriate indications
and received revascularization). Although proliferation of
cardiac technology has been the focus of recent healthcare
undergoing cardiac catheterization. A score of 1 to 3 indicates inappropriate
es appropriate indication for coronary revascularization. ACC  American Collegesease
indicatreforms (1,15), underutilization of beneficial therapy con-
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clinical practice. We observed higher risk characteristics and
more frequent comorbidities among patients who did not
receive coronary revascularization, consistent with the phe-
nomenon previously described as “treatment-risk paradox,”
a pervasive pattern in medicine in which treatment propen-
sity decreases as a result of increasing risk profiles of patients
(16,17). It is also possible that underutilization of appropri-
ate coronary revascularization is in part related to increasing
complexity of coronary artery disease.
Although proliferation of cardiac technology has been the
focus of recent healthcare reforms, underutilization of ben-
eficial therapy continues to exist for a significant proportion
of patients in clinical practice. Among patients who had
appropriate indications but no coronary revascularization,
36% were recommended medical treatment by the cardiol-
ogist, 4.5% were turned down for coronary revasculariza-
tion, and 2.6% of patients had a preference for treatment.
However, the majority of appropriate patients had no
documented reasons to explain why coronary revasculariza-
tion was not performed. In addition, we observed higher
risk characteristics and more frequent comorbidities among
patients who did not receive coronary revascularization,
consistent with the phenomenon previously described as
“treatment-risk paradox”—a pervasive pattern in medicine
in which treatment propensity decreases as a result of
increasing risk profiles of patients (18). Previously, Cabana
et al. (19) identified physician knowledge, attitude, and
external factors as the 3 main barriers as to why physicians
Figure 3 Treatment According to Appropriateness Categories
Proportions of patients undergoing medical therapy, percutaneous coronary interve
in different appropriate categories. ACC  American College of Cardiology.do not practice in accordance with guidelines.Hemingway et al. (11,12,20) previously validated appro-
priateness criteria derived in the mid-1990s and found an
association between underutilization of cardiac invasive
procedures and increased risk of adverse outcomes among
appropriate candidates. Indeed, 1 of the most important
findings of our study was the observation that coronary
revascularization was associated with lower hazards of death
or recurrent ACS in appropriate patients with stable coro-
nary artery disease using the revised criteria. This may be
surprising given the results of the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation) study, which showed no difference in clinical
outcomes between PCI and medical therapy among pa-
tients with stable coronary artery disease (21). However,
it is important to note that many patients in our study
would likely be excluded in the COURAGE trial as they
had substantial ischemic burden (40% with Canadian
Cardiovascular Society class III or IV angina, 45%
multiple vessel disease or left main stenosis, and 65%
with high-risk stress test). In fact, 40% of the appropriate
candidates in our study received CABG, which was not a
treatment option for the COURAGE patients. Indeed,
CABG was associated with a significantly lower hazard of
adverse outcomes compared with medical therapy among
patients with appropriate indications. There was no
significant different in the adjusted HRs of death or ACS
between coronary revascularization and no revasculariza-
tion in the uncertain and inappropriate category. Test of
interactions between coronary revascularization and ap-
(PCI), or coronary artery bypass grafting (CABG)ntionpropriateness category was not significant (p  0.56).
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Appropriateness of Coronary Revascularization November 6, 2012:1876–84Clinical Characteristics According to Appropriateness Categories and Coronary RevascularizationTable 1 Clinical Characteristics According to Appropriateness Categories and Coronary Revascularization
Characteristics
Inappropriate Indications Uncertain Indications Appropriate Indications
No
Revascularization
(n  170)
Revascularization
(n  141)
p
Value*
No
Revascularization
(n  150)
Revascularization
(n  176)
p
Value*
No
Revascularization
(n  311)
Revascularization
(n  680)
p
Value*
Age, yrs 65.0 9.7 62.6 10.8 0.04 65.5 10.2 63.9 9.9 0.14 66.9 10.2 65.1 10.2 0.01
Female 54 (31.8%) 39 (27.7%) 0.43 42 (28.0%) 40 (22.7%) 0.27 78 (25.1%) 156 (22.9%) 0.46
Severity of chest pain 0.22 0.32 0.08
No angina 39 (22.9%) 21 (14.9%) 49 (32.7%) 42 (23.9%) 51 (16.4%) 68 (10.0%)
CCS class I 24 (14.1%) 19 (13.5%) 19 (12.7%) 27 (15.3%) 29 (9.3%) 68 (10.0%)
CCS class II 65 (38.2%) 62 (44.0%) 65 (43.3%) 83 (47.2%) 100 (32.2%) 241 (35.4%)
CCS class III 34 (20.0%) 36 (25.5%) 16 (10.7%) 24 (13.6%) 119 (38.3%) 276 (40.6%)
CCS class IV 8 (4.7%) 5 (2.1%) 5 (0.7%) 0 (0.0%) 12 (3.9%) 27 (4.0%)
Extent of coronary disease 0.001 0.66 0.13
Mild disease (50%–69%) 44 (25.9%) 5 (2.8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
1 vessel 93 (54.7%) 75 (53.2%) 94 (62.7%) 103 (58.5%) 93 (29.9%) 198 (29.1%)
2 vessels 33 (19.4%) 60 (42.6%) 40 (26.7%) 55 (31.3%) 80 (25.7%) 170 (25.0%)
3 vessels 0 (0.0%) 5 (1.4%) 16 (10.7%) 18 (10.2%) 94 (30.2%) 176 (25.9%)
Left main stenosis 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 44 (14.1%) 136 (20.0%)
Cardiac history
Previous myocardial
infarction
33 (19.4%) 39 (27.7%) 0.09 54 (36.0%) 43 (24.4%) 0.02 96 (30.9%) 148 (21.8%) 0.002
Previous heart failure 10 (5.9%) 5 (3.5%) 0.34 11 (7.3%) 5 (2.3%) 0.03 35 (11.3%) 27 (4.0%) 0.001
Previous PCI 40 (23.5%) 26 (18.4%) 0.27 27 (18.0%) 32 (18.2%) 0.97 42 (13.5%) 89 (13.1%) 0.86
Cerebrovascular disease 10 (5.9%) 5 (3.5%) 0.34 15 (10.0%) 15 (8.5%) 0.65 27 (8.7%) 47 (6.9%) 0.33
Peripheral vascular disease 21 (12.4%) 7 (5.0%) 0.02 14 (9.3%) 11 (6.3%) 0.30 38 (12.2%) 45 (6.6%) 0.003
Cardiac risk factors and
medical comorbidities
Hypertension 108 (63.5%) 96 (68.1%) 0.40 112 (74.7%) 121 (68.8%) 0.24 237 (76.2%) 491 (72.2%) 0.19
Hyperlipidemia 124 (72.9%) 99 (70.2%) 0.60 117 (78.0%) 136 (77.3%) 0.88 266 (85.5%) 529 (77.8%) 0.01
Diabetes 55 (32.4%) 39 (27.7%) 0.37 50 (33.3%) 45 (25.6%) 0.12 113 (36.3%) 198 (29.1%) 0.02
Chronic kidney disease 41 (24.1%) 32 (22.7%) 0.77 37 (24.7%) 34 (19.3%) 0.24 95 (30.5%) 160 (23.5%) 0.02
COPD 17 (10.0%) 5 (3.5%) 0.03 15 (10.0%) 8 (4.5%) 0.06 22 (7.1%) 29 (4.3%) 0.06
Depression 9 (5.3%) 12 (8.5%) 0.26 6 (4.0%) 7 (4.0%) 0.99 20 (6.4%) 24 (3.5%) 0.04
Cancer 8 (4.7%) 5 (2.1%) 0.22 11 (7.3%) 11 (6.3%) 0.70 25 (8.0%) 38 (5.6%) 0.14
Stress test 0.19 0.10 0.06
Not done 84 (49.4%) 61 (43.3%) 38 (25.3%) 45 (25.6%) 68 (21.9%) 97 (14.3%)
Low risk 86 (50.6%) 78 (55.3%) 54 (36.0%) 84 (47.7%) 53 (17.0%) 138 (20.3%)
Intermediate risk 0 (0.0%) 5 (1.4%) 13 (8.7%) 11 (6.3%) 11 (3.5%) 25 (3.7%)
High risk 0 (0.0%) 0 (0.0%) 45 (30.0%) 36 (20.5%) 178 (57.2%) 418 (61.5%)
Number of antianginal
medications
0 40 (23.5%) 30 (21.3%) 0.30 36 (24.0%) 36 (20.5%) 0.28 47 (15.1%) 90 (13.2%) 0.56
1 95 (55.9%) 71 (50.4%) 63 (42.0%) 90 (51.1%) 132 (42.4%) 287 (42.2%)
2 29 (17.1%) 29 (20.6%) 41 (27.3%) 44 (25.0%) 97 (31.2%) 238 (35.0%)
3 6 (3.5%) 11 (7.8%) 10 (6.7%) 6 (3.4%) 35 (11.3%) 65 (9.6%)
Left ventricular ejection
fraction
0.02 0.07 0.001
60% 96 (56.5%) 70 (49.6%) 79 (52.7%) 101 (57.4%) 137 (44.1%) 375 (55.1%)
40%–59% 40 (23.5%) 35 (24.8%) 27 (18.0%) 36 (20.5%) 91 (29.3%) 169 (24.9%)
20%–39% 17 (10.0%) 7 (5.0%) 16 (10.7%) 5 (2.8%) 47 (15.1%) 32 (4.7%)
20% 5 (1.2%) 0 (0.0%) 5 (0.7%) 0 (0.0%) 12 (3.9%) 10 (1.5%)
Physician characteristics 0.11 0.002 0.01
Interventional cardiologist 46 (27.1%) 50 (35.5%) 39 (26.0%) 74 (42.0%) 81 (26.0%) 236 (34.7%)
Noninterventional
cardiologist
124 (72.9%) 91 (64.5%) 111 (74.0%) 102 (58.0%) 230 (74.0%) 444 (65.3%)
Hospital characteristics 0.23 0.32 0.36
Cath-only hospitals 41 (24.1%) 26 (18.4%) 33 (22.0%) 31 (17.6%) 51 (16.4%) 128 (18.8%)
PCI/CABG hospitals 129 (75.9%) 115 (81.6%) 117 (78.0%) 145 (82.4%) 260 (83.6%) 552 (81.2%)Values are as mean  SD or n (%). *Comparing the coronary revascularization and the no revascularization groups.
CABG  coronary artery bypass grafting; CCS  Canadian Cardiovascular Society; COPD  chronic obstructive pulmonary disease; PCI  percutaneous coronary intervention.
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health-related quality of life in patients receiving coro-
nary revascularization and medical therapy in the uncer-
tain and inappropriate categories. Therefore, we cannot
completely exclude possible beneficial effects of coronary
revascularization in these patients.
Although we observed a progressive decrease in utiliza-
tion of coronary revascularization from appropriate to un-
certain to inappropriate candidates, the revascularization
rate was still 45% in patients in the inappropriate category.
One possible reason for the relatively high inappropriate
rates is that our study cohort was assembled in 2006 to
2007, around the time the COURAGE study was published
and before the publication of the appropriateness use criteria
(6,21). On the other hand, a recent study has shown that the
COURAGE study has had little impact on contemporary
clinical practice (22). In patients with uncertain and inap-
propriate indications, we did not observe significant differ-
ences in clinical outcomes in the coronary revascularization
group and the no revascularization group, but the wide
confidence intervals of these estimates precluded conclusive
determination of whether coronary revascularization is ben-
eficial or harmful in these patients. Furthermore, we did not
have information on the severity of chest pain or health-
related quality of life after the revascularization, which may
be a more robust outcome for patients with stable coronary
artery disease.
Study limitations. Several additional limitations of our
study merit consideration. Despite our efforts to adjust for
confounding variables in comparing outcomes of patients
treated with coronary revascularization versus medical ther-
apy, patients in our cohort were not randomized and our
findings are therefore subject to selection biases and unmea-
sured confounding. In addition, only a small number of
patients experienced death or repeat ACS in the uncertain
and inappropriate categories, and thus there are greater
uncertainties in these estimates. Second, we chose a period
of 60 days after cardiac catheterization to determine the use
of coronary revascularization to take into account the wait
times for coronary revascularization in Ontario. Although it
is possible that patient status may have substantially altered
this period, many studies have demonstrated that decisions
Unadjusted Rates and Adjusted Hazards of Death or Recurrent AcuAccording to Appropriatene s Categories and Coronary RevascularTable 2 Unadjusted Rates and Adjusted H zards of D ath or RAccording to Appropriateness Categories and Coronary
Appropriateness
Category n
Crude
No
Revascularization
Inappropriate* 311 16 (9.4%)
Uncertain* 326 23 (15.3%)
Appropriate† 991 50 (16.1%)
*Hazard ratio (HR) to compare outcomes in the inappropriate and uncertain patients adjusted for ag
heart failure, peripheral vascular disease), physician characteristics, and hospital characteristics. †
(CCS angina classification, extent of coronary artery disease, hypertension, diabetes, chronic kidn
ejection fraction, physician characteristics, and hospital characteristics.
CI  confidence interval; other abbreviations as in Table 1.of coronary revascularization are made at the time of thecardiac catheterization (23). Third, we were unable to
examine the characteristics of patients within the appropri-
ate subgroup who derived the most benefit because of
limited sample size. Finally, we did not have information on
patients’ preference in their willingness to undergo or forgo
coronary revascularization.
Conclusions
Our findings provide validation to the use of appropriate-
ness use criteria in stable coronary artery disease patients to
identify underutilization and overutilization of coronary
revascularization in clinical practice. Failing to treat appro-
priate patients with coronary revascularization was associ-
ated with a significantly increased risk for adverse outcomes
at 3-year follow-up, whereas treating inappropriate patients
was not associated with lower mortality or readmission rates
for ACS.
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